Related Experiment Video
Updated: Aug 18, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Polygenic risk scores for the prediction of cardiometabolic disease
Jack W O'Sullivan1,2, Euan A Ashley1,2,3, Perry M Elliott4,5
1Stanford Center for Inherited Cardiovascular Disease, Stanford University School of Medicine, Stanford, CA, USA.
Insights
Polygenic risk scores (PRSs) enhance prediction for cardiometabolic diseases like coronary artery disease and type 2 diabetes. While promising for conditions including atrial fibrillation, further research is needed for broader clinical use.
Area of Science:
- Genetics and Precision Medicine
- Cardiovascular and Metabolic Research
Background:
- Cardiometabolic diseases are a leading cause of global morbidity and mortality.
- Polygenic risk scores (PRSs) integrate multiple genetic variants to predict disease risk.
- This review examines PRS utility across seven common cardiometabolic conditions.
Approach:
- Systematic review of evidence for PRS in coronary artery disease (CAD), stroke, hypertension, heart failure, cardiomyopathies, obesity, atrial fibrillation (AF), and type 2 diabetes mellitus (T2DM).
- Evaluation of PRS performance in improving clinical prediction models.
Key Points:
- PRS for CAD, AF, and T2DM show consistent improvement in prediction when added to existing clinical risk tools.
- PRS application for ischaemic stroke and hypertension is currently premature.
- Larger, diverse populations and refined phenotyping are crucial for advancing PRS clinical utility.
Conclusions:
- PRS represent a significant advancement in predicting cardiometabolic disease development and complications.
- Clinical implementation of PRS is most robust for CAD, AF, and T2DM.
- Future research directions include expanding PRS utility through diverse cohorts and detailed phenotyping.
Abstract:
Cardiometabolic diseases contribute more to global morbidity and mortality than any other group of disorders. Polygenic risk scores (PRSs), the weighted summation of individually small-effect genetic variants, represent an advance in our ability to predict the development and complications of cardiometabolic diseases. This article reviews the evidence supporting the use of PRS in seven common cardiometabolic diseases: coronary artery disease (CAD), stroke, hypertension, heart failure and cardiomyopathies, obesity, atrial fibrillation (AF), and type 2 diabetes mellitus (T2DM). Data suggest that PRS for CAD, AF, and T2DM consistently improves prediction when incorporated into existing clinical risk tools. In other areas such as ischaemic stroke and hypertension, clinical application appears premature but emerging evidence suggests that the study of larger and more diverse populations coupled with more granular phenotyping will propel the translation of PRS into practical clinical prediction tools.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Coronary Artery Disease I: Introduction
Polygenic Traits
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Obesity

